Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
4.7000
-0.1650 (-3.39%)
NASDAQ · Last Trade: Sep 1st, 9:26 PM EDT
Detailed Quote
Previous Close
4.865
Open
4.840
Bid
4.680
Ask
4.700
Day's Range
4.630 - 4.895
52 Week Range
3.790 - 12.36
Volume
15,124,847
Market Cap
791.60M
PE Ratio (TTM)
-2.582
EPS (TTM)
-1.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
17,566,556
Chart
About Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
Recursion Pharmaceuticals Inc is a biotechnology company focused on leveraging advanced computational biology and machine learning techniques to transform drug discovery and development. By utilizing a proprietary platform that integrates high-throughput biology and data science, the company aims to identify new therapeutic targets and accelerate the process of discovering novel medicines for a variety of diseases. Their innovative approach seeks to uncover hidden connections in biological data, enabling them to explore previously uncharted areas in the pharmaceutical landscape and bring forth breakthrough treatments for patients in need. Read More
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and
Salt Lake City, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:
Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per share, missing estimates for a loss of 34 cents per share.
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7)
The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This shift moves beyond generic interactions, creating highly tailored and dynamic digital environments that promise to revolutionize user experience across entertainment, e-commerce, and healthcare. The immediate
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
In the rapidly evolving world of technology, a groundbreaking frontier is emerging that could redefine the very nature of computation: biocomputers. Unlike traditional computers built from silicon-based microchips, biocomputers harness the remarkable processing power of biological systems—often using living cells, DNA molecules, or even entire organisms as computational platforms.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a notable surge in its stock price as investor enthusiasm for artificial intelligence-driven biotechnology reached new highs. The rally comes amid growing confidence in the company’s platform, which combines advanced machine learning with high-throughput biological experimentation, signaling a potential paradigm shift in the
